Andrew Benjamin Nixon, PhD

Associate Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Ronald, James, Andrew B. Nixon, Daniele Marin, Rajan T. Gupta, Gemini Janas, Willa Chen, Paul V. Suhocki, et al. “Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma..” Radiology 285, no. 1 (October 2017): 311–18. https://doi.org/10.1148/radiol.2017162555.

PMID
28787261
Full Text

Corradetti, M. N., A. J. Hatch, J. Torok, E. P. Xanthopoulos, C. N. Rushing, J. Calaway, G. Jones, A. B. Nixon, and C. R. Kelsey. “Dynamic Changes in Cell-Free DNA During Chemoradiation for Non–small Cell Lung Cancer.” In International Journal of Radiation Oncology*Biology*Physics, 99:S114–15. Elsevier BV, 2017. https://doi.org/10.1016/j.ijrobp.2017.06.270.

Full Text

Thompson, Eric M., Stephen T. Keir, Talaignair Venkatraman, Christopher Lascola, Kristen W. Yeom, Andrew B. Nixon, Yingmiao Liu, et al. “The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival..” Neuro Oncol 19, no. 9 (September 1, 2017): 1217–27. https://doi.org/10.1093/neuonc/nox033.

PMID
28379574
Full Text

Liu, Yingmiao, Zhenhua Yuan, Dadong Zhang, Mark D. Starr, John C. Brady, Manoj A. Jivani, Bonne J. Adams, et al. “Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy..” In Journal of Clinical Oncology, 35:11546–11546. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.11546.

Full Text

Sinicrope, Frank A., Fang-Shu Ou, Qian Shi, Andrew B. Nixon, Kabir Mody, Alexandra Levasseur, Amylou C. Dueck, et al. “Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC, Alliance A021502)..” In Journal of Clinical Oncology, 35:TPS3630–TPS3630. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.tps3630.

Full Text

George, Daniel J., Susan Halabi, Mark D. Starr, Herbert Hurwitz, John C. Brady, Ian Barak, Michael J. Morris, et al. “Association of on-treatment plasma HGF levels with overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (INF) +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)..” In Journal of Clinical Oncology, 35:4522–4522. American Society of Clinical Oncology (ASCO), 2017. https://doi.org/10.1200/jco.2017.35.15_suppl.4522.

Full Text

Hesler, Rachel A., Jennifer J. Huang, Mark D. Starr, Victoria M. Treboschi, Alyssa G. Bernanke, Andrew B. Nixon, Shannon J. McCall, Rebekah R. White, and Gerard C. Blobe. “TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3..” Carcinogenesis 37, no. 11 (November 2016): 1041–51. https://doi.org/10.1093/carcin/bgw093.

PMID
27604902
Full Text

Zhang, Tian, Jason Zhu, Daniel J. George, and Andrew B. Nixon. “Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies..” Urol Oncol 34, no. 11 (November 2016): 510–18. https://doi.org/10.1016/j.urolonc.2016.06.020.

PMID
27498927
Full Text

Hatch, Ace J., Alexander B. Sibley, Mark D. Starr, J Chris Brady, Chen Jiang, Jingquan Jia, Daniel L. Bowers, et al. “Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)..” Cancer Med 5, no. 9 (September 2016): 2249–60. https://doi.org/10.1002/cam4.806.

PMID
27465221
Full Text

Keefe, S. M., J. Hoffman-Censits, R. B. Cohen, R. Mamtani, D. Heitjan, S. Eliasof, A. Nixon, et al. “Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial..” Ann Oncol 27, no. 8 (August 2016): 1579–85. https://doi.org/10.1093/annonc/mdw188.

PMID
27457310
Full Text

Pages